tradingkey.logo
tradingkey.logo
Search

Nexalin Technology Says Q-Submission To Facilitate Dialogue With FDA On Clinical Trial Design

ReutersMay 1, 2025 4:26 PM
facebooktwitterlinkedin
View all comments0

- Nexalin Technology Inc NXL.O:

  • NEXALIN TECHNOLOGY INITIATES FDA Q-SUBMISSION PROCESS FOR GEN-2 SYNC FOLLOWING ENCOURAGING DATA AND PRELIMINARY FDA FEEDBACK

  • NEXALIN TECHNOLOGY INC - Q-SUBMISSION TO FACILITATE DIALOGUE WITH FDA ON CLINICAL TRIAL DESIGN

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI